NASDAQ:UTHR United Therapeutics Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding United Therapeutics Co. Please log in to your account or sign up in order to add this asset to your watchlist. $235.38 -0.26 (-0.11%) (As of 07/1/2022 12:19 PM ET) Add Compare Share Today's Range$232.87▼$236.3350-Day Range$174.81▼$241.1452-Week Range$158.38▼$243.30Volume2,929 shsAverage Volume479,542 shsMarket Capitalization$10.66 billionP/E Ratio16.29Dividend YieldN/APrice Target$244.50 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive UTHR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for United Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address UTHR Stock Forecast (MarketRank)Overall MarketRank™2.25 out of 5 starsMedical Sector340th out of 1,429 stocksPharmaceutical Preparations Industry141st out of 682 stocksAnalyst Opinion: 1.4Community Rank: 4.0Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 2.5 5 -4 -3 -2 -1 - 1.4 Analyst's Opinion Consensus RatingUnited Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $244.50, United Therapeutics has a forecasted upside of 4.7% from its current price of $233.42.Amount of Analyst CoverageUnited Therapeutics has only been the subject of 4 research reports in the past 90 days. Previous Next 4.0 Community Rank Outperform VotesUnited Therapeutics has received 516 “outperform” votes. (Add your “outperform” vote.)Underperform VotesUnited Therapeutics has received 340 “underperform” votes. (Add your “underperform” vote.)Community SentimentUnited Therapeutics has received 60.28% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about United Therapeutics and other stocks. Vote “Outperform” if you believe UTHR will outperform the S&P 500 over the long term. Vote “Underperform” if you believe UTHR will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldUnited Therapeutics does not currently pay a dividend.Dividend GrowthUnited Therapeutics does not have a long track record of dividend growth. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, United Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $10,773,740.00 in company stock.Percentage Held by Insiders12.10% of the stock of United Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions94.68% of the stock of United Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for United Therapeutics are expected to grow by 10.04% in the coming year, from $17.23 to $18.96 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of United Therapeutics is 16.15, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 39.73.Price to Earnings Ratio vs. SectorThe P/E ratio of United Therapeutics is 16.15, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 36.69.Price to Earnings Growth RatioUnited Therapeutics has a PEG Ratio of 5.29. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioUnited Therapeutics has a P/B Ratio of 2.66. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About United Therapeutics (NASDAQ:UTHR)United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension associated with interstitial lung disease (PH-ILD); Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. The company also engages in developing Tyvaso DPI, a dry powder inhalation form of Tyvaso; Remunity Pump, a small, lightweight, durable pump and separate controller; RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Tyvaso PERFECT and TETON studies, which are the studies of Tyvaso in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.Read More UTHR Stock News HeadlinesJuly 1, 2022 | americanbankingnews.comUnited Therapeutics (NASDAQ:UTHR) Reaches New 12-Month High at $243.30June 29, 2022 | seekingalpha.comLiquidia Vs. MannKind: Treprostinil Is The Big 'IF'June 27, 2022 | finance.yahoo.comAbbVie's (ABBV) Rinvoq Gets CHMP Nod for New IndicationJune 27, 2022 | finance.yahoo.comZacks.com featured highlights include Sanderson Farms, United Therapeutics, AMN HealthcareJune 27, 2022 | finance.yahoo.comNovartis (NVS) Gets Positive CHMP Opinion for Scemblix in CMLJune 24, 2022 | finance.yahoo.comBuy These 3 Low-Beta Stocks to Sail Through a Choppy MarketJune 22, 2022 | finance.yahoo.comDow Jones Rises, Techs Lead As Fed Chief Powell Minimizes Recession RisksJune 22, 2022 | finance.yahoo.comDow Jones Falls As Fed Chief Powell Minimizes Recession RisksJune 21, 2022 | finance.yahoo.comBiotech Stock United Therapeutics Revives Breakout, Retakes Buy ZoneJune 14, 2022 | finance.yahoo.comMontgomery County to weigh more stringent energy standards for some new constructionJune 10, 2022 | benzinga.comWill Investors Notice Exciting Sign On United Therapeutics's Chart?June 7, 2022 | uk.finance.yahoo.comAssessing the impact of economic shocks on the United Therapeutics share priceJune 3, 2022 | finance.yahoo.comWhy Is United Therapeutics (UTHR) Up 22.1% Since Last Earnings Report?See More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:UTHR CUSIP91307C10 CIK1082554 Webwww.unither.com Phone(301) 608-9292Fax301-608-9291Employees965Year Founded1996Company Calendar Last Earnings5/04/2022Today7/01/2022Next Earnings (Estimated)8/03/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$244.50 High Stock Price Forecast$300.00 Low Stock Price Forecast$203.00 Forecasted Upside/Downside+3.9%Consensus RatingModerate Buy Rating Score (0-4)2.85714285714286 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)$14.45 Trailing P/E Ratio16.29 Forward P/E Ratio13.66 P/E Growth5.29Net Income$475.80 million Net Margins38.87% Pretax Margin49.21% Return on Equity17.62% Return on Assets13.46% Debt Debt-to-Equity Ratio0.19 Current Ratio8.84 Quick Ratio8.54 Sales & Book Value Annual Sales$1.69 billion Price / Sales6.33 Cash Flow$11.50 per share Price / Cash Flow20.47 Book Value$87.90 per share Price / Book2.68Miscellaneous Outstanding Shares45,300,000Free Float39,819,000Market Cap$10.66 billion OptionableOptionable Beta0.62 Social Links United Therapeutics Frequently Asked Questions Should I buy or sell United Therapeutics stock right now? 7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for United Therapeutics in the last year. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" United Therapeutics stock. View analyst ratings for United Therapeutics or view top-rated stocks. What is United Therapeutics' stock price forecast for 2022? 7 Wall Street research analysts have issued 1 year price targets for United Therapeutics' shares. Their UTHR stock forecasts range from $203.00 to $300.00. On average, they predict United Therapeutics' share price to reach $244.50 in the next twelve months. This suggests a possible upside of 4.2% from the stock's current price. View analysts' price targets for United Therapeutics or view top-rated stocks among Wall Street analysts. How has United Therapeutics' stock performed in 2022? United Therapeutics' stock was trading at $216.08 at the beginning of the year. Since then, UTHR stock has increased by 8.6% and is now trading at $234.64. View the best growth stocks for 2022 here. When is United Therapeutics' next earnings date? United Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 3rd 2022. View our earnings forecast for United Therapeutics. How were United Therapeutics' earnings last quarter? United Therapeutics Co. (NASDAQ:UTHR) posted its quarterly earnings results on Wednesday, May, 4th. The biotechnology company reported $5.03 EPS for the quarter, topping the consensus estimate of $2.96 by $2.07. The biotechnology company had revenue of $461.90 million for the quarter, compared to analyst estimates of $420.02 million. United Therapeutics had a net margin of 38.87% and a trailing twelve-month return on equity of 17.62%. The firm's revenue for the quarter was up 21.8% on a year-over-year basis. During the same period in the prior year, the firm earned $0.61 EPS. View United Therapeutics' earnings history. Who are United Therapeutics' key executives? United Therapeutics' management team includes the following people: Dr. Martine A. Rothblatt J.D., M.B.A., Ph.D., Founder, Chairman & CEO (Age 67, Pay $3.51M)Mr. Michael I. Benkowitz, Pres & COO (Age 50, Pay $1.96M)Mr. James C. Edgemond, CFO & Treasurer (Age 54, Pay $1.42M)Mr. Paul A. Mahon J.D., Exec. VP, Gen. Counsel & Corp. Sec. (Age 58, Pay $1.67M)Mr. Dewey Steadman C.F.A., Head of Investor RelationsMs. Holly Hobson, Associate VP of HRKevin T. Gray, Sr. VP of Strategic Operations & LogisticsMr. Patrick Poisson, Exec. VP of Technical Operations (Age 54)Mr. Gil Golden, Sr. VP & Chief Medical OfficerDr. Leigh Peterson, VP of Product Devel. What is Martine A. Rothblatt's approval rating as United Therapeutics' CEO? 64 employees have rated United Therapeutics CEO Martine A. Rothblatt on Glassdoor.com. Martine A. Rothblatt has an approval rating of 88% among United Therapeutics' employees. Who are some of United Therapeutics' key competitors? Some companies that are related to United Therapeutics include Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Seagen (SGEN), Biogen (BIIB), Alnylam Pharmaceuticals (ALNY), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Neurocrine Biosciences (NBIX), Repligen (RGEN), Exact Sciences (EXAS), Exelixis (EXEL), Halozyme Therapeutics (HALO) and Ionis Pharmaceuticals (IONS). View all of UTHR's competitors. What other stocks do shareholders of United Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other United Therapeutics investors own include Gilead Sciences (GILD), NVIDIA (NVDA), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), (CELG), General Electric (GE), Johnson & Johnson (JNJ), Skyworks Solutions (SWKS), Allergan (AGN) and Pfizer (PFE). What is United Therapeutics' stock symbol? United Therapeutics trades on the NASDAQ under the ticker symbol "UTHR." How do I buy shares of United Therapeutics? Shares of UTHR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is United Therapeutics' stock price today? One share of UTHR stock can currently be purchased for approximately $234.64. How much money does United Therapeutics make? United Therapeutics (NASDAQ:UTHR) has a market capitalization of $10.63 billion and generates $1.69 billion in revenue each year. The biotechnology company earns $475.80 million in net income (profit) each year or $14.45 on an earnings per share basis. How many employees does United Therapeutics have? United Therapeutics employs 965 workers across the globe. When was United Therapeutics founded? United Therapeutics was founded in 1996. How can I contact United Therapeutics? United Therapeutics' mailing address is 1040 SPRING ST, SILVER SPRING MD, 20910. The official website for United Therapeutics is www.unither.com. The biotechnology company can be reached via phone at (301) 608-9292, via email at [email protected], or via fax at 301-608-9291. This page (NASDAQ:UTHR) was last updated on 7/1/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
